CD226 anticorps (FITC)

N° du produit ABIN1449203

Détail du produit anti-CD226 anticorps (FITC)

Antigène: CD226

Reactivité: Humain

Hôte: Rat

Clonalité: Monoclonal

Conjugué: Cet anticorp CD226 est conjugé à/à la FITC

Application: Flow Cytometry (FACS)

Specificité: This antibody reacts with human CD226/DNAM-1.

Purification: Protein G agarose

Immunogène: Recombinant human CD226/DNAM-1

Clone: TX25

Isotype: IgG2a

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Concentration: 0.5 mg/mL

Buffer: PBS, 0.09 % NaN3, 1 % BSA

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C

Stockage commentaire: Store at 2-8 °C.

Détails sur CD226

Antigène: CD226

Autre désignation: CD226 / DNAM1 (CD226 Produits)

Synonymes: anticorps CD226, anticorps cd226, anticorps zgc:158817, anticorps BC051526, anticorps DNAM-1, anticorps DNAM1, anticorps Pta1, anticorps TLiSA1, anticorps PTA1, anticorps CD226 molecule, anticorps CD226 antigen, anticorps CD226, anticorps cd226, anticorps Cd226

Sujet: CD226/DNAM-1 (DNAX accessory molecule-1) is a 65 kDa type I transmembrane glycoprotein expressed on the majority of T cells, NK cells, monocytes, and a subset of B-cells. A soluble form (50 kDa) of CD226 is present in normal serum and the supernatant of cultured activated T cells. Ligand binding to CD226 results in phosphorylation of Ser329 and Tyr322, suggesting a role in signal transduction. CD226 acts as an adhesion molecule involved in the binding of certain tumor cells to CTL and NK cells and mediates their cytotoxicity. CD226 also stimulates TNF-α and IFN-γ secretion by alloantigen-specific T cells.Synonyms: DNAM-1, DNAX accessory molecule 1

ID gène: 10666

NCBI Accession: NP_006557

UniProt: Q15762

Pathways: Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints